Dubrot J, Lane-Reticker SK, Kessler EA, et al. In vivo screens using a selective CRISPR antigen removal lentiviral vector system reveal immune dependencies in renal cell carcinoma. Immunity. 2021;54(3):571-585.e6. doi:10.1016/j.immuni.2021.01.001
Publications
Braun DA, Street K, Burke KP, et al. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell. 2021. doi:10.1016/j.ccell.2021.02.013
Lazarian G, Yin S, Hacken ET, et al. A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation. Cancer Cell. 2021;39(3):380-393.e8. doi:10.1016/j.ccell.2021.02.003
Ngo D, Benson MD, Long JZ, et al. Proteomic profiling reveals biomarkers and pathways in type 2 diabetes risk. JCI Insight. 2021;6(5). doi:10.1172/jci.insight.144392
Cissé OH, Ma L, Dekker JP, et al. Genomic insights into the host specific adaptation of the Pneumocystis genus. Commun Biol. 2021;4(1):305. doi:10.1038/s42003-021-01799-7
Chamberlain BT, Vincent M, Nafie J, Müller P, Greka A, Wagner FF. Multigram Preparation of BRD4780 Enantiomers and Assignment of Absolute Stereochemistry. J Org Chem. 2021;86(5):4281-4289. doi:10.1021/acs.joc.0c02520
Hahn WC, Bader JS, Braun TP, et al. An expanded universe of cancer targets. Cell. 2021;184(5):1142-1155. doi:10.1016/j.cell.2021.02.020
Sinnott-Armstrong N, Sousa IS, Laber S, et al. A regulatory variant at 3q21.1 confers an increased pleiotropic risk for hyperglycemia and altered bone mineral density. Cell Metab. 2021;33(3):615-628.e13. doi:10.1016/j.cmet.2021.01.001
Graubert A, Aguet F, Ravi A, Ardlie KG, Getz G. RNA-SeQC 2: Efficient RNA-seq quality control and quantification for large cohorts. Bioinformatics. 2021. doi:10.1093/bioinformatics/btab135
Jan M, Sperling AS, Ebert BL. Cancer therapies based on targeted protein degradation - lessons learned with lenalidomide. Nat Rev Clin Oncol. 2021. doi:10.1038/s41571-021-00479-z